Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Bortenat 2 mg

Bortezomib-Bortenat2mg

Availability: In stock

Special Price $ 0

BRAND : NATCO
STRENGTH : 2mg
INGREDIENT : Bortezomib-Bortenat2mg
COMPANY NAME : NATCO
COUNT : 1 Tablets



Description of Bortenat 2 mg

Product profile: Trade name: Bortenat Active component: Bortezomib Strength of the component: 2mg vial Mfg: Natco pharma Pack: 2mg Bortezomib containing vial in a carton Dosage form: lyophilized powder Category: Anti-cancer drug; proteasome inhibitor Bortenat description: Bortenat is an anti-neoplastic medicine, which is available in the form of lyophilized powder Bortenat is available in the strength of 2MG Bortenat is a prime benign proteasome inhibitor; proteasome is a biological structure that clefts the proteins Bortenat is FDA approved product which is used to treat; • Mantle cell lymphoma • Multiple myeloma Pharmacological grouped as: anti-neoplastic agent or proteasome inhibitor

Pharmacology of Bortenat 2 mg

Bortenat mechanism of action: Bortenat is a chymotrypsin like activity unstable prohibitor of the 26S proteasome in human cells. The 26S proteasome is a complex protein that decrease the agglutinated proteins The assorted proteins are weakens by proteasome enzymes which difficult to cancer cells durability like cyclins, tumor suppressors, BCL-2 & cyclin dependent kinase inhibitors The functioning site of proteasome has Postglutamyl peptide hydrolysis activity Chymotrypsin like Trypsin like Prohibition of these degenerations, sensitizes cells to apoptosis and cell arrest and causes cell lysis Pharmacokinetic: Absorption: The absorption of Bortenat is acceptable The peak plasma level of Bortenat occurs as 509ng/ml Distribution: The volume of distribution is 498 to 1884L/m2 The human plasma protein binding of Bortenat occurs as nearly 83% Metabolism: The Major metabolic pathway of Bortenat is occurs by deboronation to form 2-deboronated metabolites which are inactive as 26S proteasome inhibitors Bortenat is metabolized in liver with the help of cytochrome P 450 enzymes 3A4, 2C19, & 1A2 by oxidation Elimination: In single dose IV: The half life period of Bortenat occurs at 9 to 15 hours; Multiple 1mg/m2 dosing: 40 to 193 hours Multiple 1.3mg/m2 dosing: 76 to 108 hours

Indication of Bortenat 2 mg

Bortenat is majorly used to treat Multiple myeloma Mantle cell lymphoma

Dose & Dosage's of Bortenat 2 mg

Generally Bortenat is in lyophilized powder form; which is reconstituted by using 0.9% normal saline (NS) NaCl Bortenat 2mg should be reconstituted in 2ml of 0.9% NS The route of administration is IV bolus Intrathecal not use for administration In adults: Multiple myeloma: In the therapy of previously untreated multiple myeloma: 1.3mg/m2 of Bortenat dose should be administered as 3 to 5 seconds through IV bolus or subcutaneous by combining with tablet melphalan and prednisolone for nine 6 weeks therapy cycles Cycles 1 over 4, Bortenat is taken for two times weekly, (day 1, 4, 8, 11, 22, 25, 29 and 32) Cycles 5 over 9, Bortenat is taken once a week (day 1, 8, 22, and 29) Key points: Partially, 72 hours should be passing between following doses of Bortenat In Relapse stage: The recommended dose of Bortenat is 1.3mg/m2 should be administered through IV bolus or subcutaneous as two times for two weeks (day1, 4, 8, and 11) followed by a ten day rest course (day 12 through 21) Treatment schedule increased above 8 cycles may be taken once weekly for 4 weeks (day 1, 8, 15, and 22), followed by 13 day rest (day 23 over 35) Important points: Bortenat should be used alone or combination with dexamethasone Three week course is considered as therapy cycle A minimum 72 hours should slip away between constant doses of Bortenat Mantle cell lymphoma: The usual dose of Bortenat for untreated mantle cell lymphoma is; 1.3mg/m2 of Bortenat given as IV bolus given as two times weekly by combining with rituximab, cyclophospahmide, doxorubicin and tablet prednisolone for two weeks (day I, IV, VIII & XI) followed by 10 day rest period (day II through 21) In Relapse stage: The recommended dose of Bortenat is 1.3mg/m2 administered as IV bolus or subcutaneous two times for two weeks (day I, IV, VIII & XI) followed by 10 day rest period (day II through 21) The treatment continued for above 8 cycles may be taken for once weekly for 4 weeks (day 1, 8, 15 & 22), followed by 13 day rest (days 23 through 35) Missed dose: Bortenat is not a normal medicine used as anti-cancer drug; it is not to be self-medicated If patient fail to take the dose of Bortenat, must consult with medical oncologist and followed the dosing schedules Do not self administered Follow the advice given by physician and do not missed the cycles for course of therapy

Side Effects of Bortenat 2 mg

Most common side effects occurred after administration of Bortenat includes; Burning, crawling, itching, numbness, prickling Chest pain Black tarry stools Bleeding gums Blood in urine Blurred vision Body aches Cough producing mucus, dizziness, faintness, nerve pain, painful urination, pale skin, runny nose, sore throat, stuffy nose, swollen glands, sunken eyes, ulcer, dry mouth, ear congestion, loss of voice Less common side effects: Dilated veins, discomfort, increased sensitivity of pain & touch, irregular breathing, heart beats, swelling of peripheral organs, thickening of bronchial secretions Belching, bone pain, difficulty with moving & bowel movements, cold and shivering, loss of appetite, loss of taste, muscle cramps, muscle pain, stomach discomfort. Vomiting, loss of weight

Contraindication of Bortenat 2 mg

Bortenat is given through IV bolus or subcutaneous; whereas intrathecal administration is contraindicated to the patients who are receiving Bortezomib Hypersensitivity reaction occurs in patients who are contraindicated to Bortenat, boron, boric acid or glycine

Drug Interaction of Bortenat 2 mg

Avoid concomitant with st. Johns wort to decrease the exposure of Bortenat Strong CYP3A4 inhibitors: there is a chance of getting Bortenat toxicity; so to reduce the dose of Bortenat while concomitant with CYP3A4 inhibitors Strong CYP3A4 inducers: decrease the exposure of Bortenat No clinical effect on Bortenat exposure while concomitant with melphalan-prednisone or dexamethasone alone

Precaution of Bortenat 2 mg

While taking Bortenat some adverse effects occurs care should be taken in the conditions like Cardiac toxicity Pulmonary toxicity like Acute Respiratory Distress Syndrome, pneumonitis, interstitial pneumonia, lung infiltration Posterior reversible encephalopathy syndrome-stop the Bortenat therapy Bortenat leads to peripheral neuropathy like burning sensation, hyperesthesia, hypoesthesia, paresthesia, neuropathic pain Manage postural Hypotension by altering the antihypertensive agents, hydration, and administration of mineralocorticoids or sympathomimetics Gastrointestinal toxicity-fluid or electrolyte replacements have to take Thrombocytopenia and neutropenia Tumor lysis syndrome Hepatic toxicity Embryo fetal toxicity

Usage & Safety profile of Bortenat 2 mg Pregnancy & Lactation

Bortenat is not recommended in pregnancy condition. Bortenat causes fetal harm and leads to some adverse effect Breast feeding is not recommended

Storage of Bortenat 2 mg

Bortenat vial should be stored at 20oC to 25oC (68oF to 77oF); excursion between 15oC to 30oC (59oF to 86oF) Keep away from light and heat